
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology |
Second Department of Biochemistry [Y. M., Y. Y., S. O.], Third Department of Internal Medicine [Y. M., S. N., A. T., N. K.], and Second Department of Surgery [S. K., K. H.], Osaka City University Medical School, Osaka 545-8585, Japan
IFN regulatory factor-1 (IRF-1) regulates the IFN system, inhibits cell growth, and has tumor-suppressor activities. p21 is a universal cyclin-dependent kinase inhibitor, the induction of which depends on both p53 and IRF-1 in mouse embryonic fibroblasts. The expression of p21 in hepatocellular carcinomas (HCCs) is regulated by wild-type p53. We examined the expressions of IRF-1 and p21 in 32 HCCs by quantitative reverse transcription-PCR and the mutation p53 gene in 32 HCCs by single-strand conformation polymorphism and direct sequencing. The expression of IRF-1 mRNA in 15 of 32 HCCs was lower than that in adjacent noncancerous tissue. IRF-1 mRNA expression was reduced in 0 of 3 specimens of well-differentiated HCC, 9 of 21 (42%) specimens of moderately differentiated HCC, and 6 of 8 (75%) specimens of poorly differentiated HCC. IRF-1 mRNA expression was significantly lower in tumors with portal thrombus than in those without portal thrombus (P = 0.003). p53 mutations were detected in 7 of 32 HCCs. p21 expression was reduced in 6 of the 7 (86%) HCCs with p53 mutations. In contrast, p21 expression was reduced in 13 of 25 (52%) HCCs with wild-type p53. IRF-1 expression was reduced in 7 of 13 (53%) HCCs with both wild-type p53 and reduced expression of p21. These results suggest that IRF-1 may be a tumor-suppressor gene for HCC and that IRF-1 is related to p21 expression in HCC with wild-type p53.
This article has been cited by other articles:
![]() |
C. M. Bailey, D. E. Abbott, N. V. Margaryan, Z. Khalkhali-Ellis, and M. J. C. Hendrix Interferon Regulatory Factor 6 Promotes Cell Cycle Arrest and Is Regulated by the Proteasome in a Cell Cycle-Dependent Manner Mol. Cell. Biol., April 1, 2008; 28(7): 2235 - 2243. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Park, K. Kim, E.-J. Lee, Y.-J. Seo, S.-N. Lim, K. Park, S. B. Rho, S.-H. Lee, and J.-H. Lee Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis PNAS, October 23, 2007; 104(43): 17028 - 17033. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, D.-P. Liu, P.-P. Chen, H. P. Koeffler, X.-J. Tong, and D. Xie Involvement of IFN Regulatory Factor (IRF)-1 and IRF-2 in the Formation and Progression of Human Esophageal Cancers Cancer Res., March 15, 2007; 67(6): 2535 - 2543. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Bailey, Z. Khalkhali-Ellis, S. Kondo, N. V. Margaryan, R. E. B. Seftor, W. W. Wheaton, S. Amir, M. R. Pins, B. C. Schutte, and M. J. C. Hendrix Mammary Serine Protease Inhibitor (Maspin) Binds Directly to Interferon Regulatory Factor 6: IDENTIFICATION OF A NOVEL SERPIN PARTNERSHIP J. Biol. Chem., October 7, 2005; 280(40): 34210 - 34217. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |